FRANKFURT (Reuters) – Fresenius Medical Care AG said that a $231.7 million U.S. settlement reached on Friday to resolve bribery allegations would have no impact on its 2019 and 2020 results because it had already made a financial provision last year.
“Given these accruals already made, the resolutions will have no effect on the company’s 2019 and 2020 outlook,” the Germany-based dialysis clinic operator said after the U.S. Justice Department announced the settlement.
Reporting by Douglas Busvine, editing by Louise Heavens
Our Standards:The Thomson Reuters Trust Principles.
